This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Hypera-Sanofi deal faces more scrutiny in Brazil after being declared 'complex'

By Ana Paula Candil ( December 20, 2021, 21:48 GMT | Insight) -- Hypera's planned buyout of 12 medicine brands from Sanofi Medley Farmacêutica has been declared "complex" by the Brazilian competition authority and will require an in-depth analysis because of what the agency deemed high concentration levels in certain markets. They include stimulant laxatives and prescription nasal decongestants. Hypera's planned buyout of 12 medicine brands from Sanofi Medley Farmacêutica has been declared "complex" by the Brazilian competition authority and will require an in-depth analysis because of what the agency deemed high concentration levels in certain markets....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login